Quote | Tempest Therapeutics Inc. (NASDAQ:TPST)
Last: | $3.38 |
---|---|
Change Percent: | -0.29% |
Open: | $3.41 |
Close: | $3.38 |
High: | $3.5839 |
Low: | $3.35 |
Volume: | 329,490 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
News | Tempest Therapeutics Inc. (NASDAQ:TPST)
2024-05-09 17:46:40 ET More on Tempest Therapeutics Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Te...
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced soli...
Message Board Posts | Tempest Therapeutics Inc. (NASDAQ:TPST)
Subject | By | Source | When |
---|---|---|---|
There is life out there. Don't give up!!!! Never, | Gator44 | investorshub | 05/01/2023 7:11:13 AM |
$TPST MomentumIts now | tw0122 | investorshub | 04/29/2023 10:34:11 PM |
For sure ..Tempest Announces Positive Early Results from | tw0122 | investorshub | 04/28/2023 1:21:42 PM |
News | Awl416 | investorshub | 04/28/2023 1:08:05 PM |
great news | tw0122 | investorshub | 04/25/2023 11:43:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced soli...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...